btrx-246040 btrx-246040 btrx-246040, also known as ly-2940094, is a potent and selective nociceptin receptor antagonist which is under development by blackthorn therapeutics and eli lilly for the treatment of major depressive disorder (mdd). it has demonstrated proof-of-concept clinical efficacy for depression. as of 2017, it is in phase ii clinical trials for the treatment of mdd. it was also under investigation for the treatment of alcoholism, and similarly reached phase ii clinical studies for this indication, but development was discontinued. btrx-246040clinical dataother namesbtrx-246040routes ofadministrationby mouthlegal statuslegal status investigational identifiers iupac name pyran-7,4'-piperidine]-1'-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol cas number1307245-86-8chemspider34248711unii4i67us2v8qchemblchembl3304244chemical and physical dataformulac22h23clf2n4o2smolar mass480.96 g·mol−13d model (jsmol)interactive image smiles cc1c(cn(n1)c2c(cccn2)co)cn3ccc4(cc3)c5c(cc(s5)cl)c(co4)(f)f inchi inchi=1s/c22h23clf2n4o2s/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30h,4-5,7-8,10,12-13h2,1h3key:nkqhbjnrbkhuqr-uhfffaoysa-n